Skip to main content
Case Studies

Documented cases, examined clearly.

Structured examinations of cancer cases | clinical context, chronology, findings, and interpretation, presented as educational reference material.

CS-005Not formally staged (no TNM given); mediastinal and left hilar lymph node enlargement with sigmoid colon and later left adrenal gland metastases

SMARCA4-Deficient NSCLC with Rare Sigmoid Colon and Adrenal Metastases: A Case Report

A 59-year-old man with SMARCA4-deficient non-small cell lung cancer developed rare sigmoid colon and adrenal gland metastases, later responding favorably to an adjusted chemo-immunotherapy regimen.

Non-small cell lung cancer (NSCLC) with SMARCA4 gene deletionFrom initial presentation through post-treatment follow-up; exact duration not specified in the sourceA SMARCA4-deficient NSCLC case featuring an atypical sigmoid colon metastasis and subsequent adrenal metastasis, with disease progression on initial chemo-immunotherapy and radiotherapy followed by a favorable response to a switched gemcitabine, nedaplatin, bevacizumab, and camrelizumab regimen.
Read case→
CS-004Not reported in the source

CD19 CAR-T Therapy Produces Durable Remission in TP53-Mutated, Triple-Refractory Burkitt Lymphoma

A 16-year-old male with TP53-mutated Burkitt lymphoma, initially misdiagnosed and refractory to three chemotherapy regimens, achieved complete metabolic response and remains in remission 30 months after CD19-directed CAR-T cell therapy (axicabtagene ciloleucel).

Burkitt lymphoma (TP53-mutated)From initial presentation through 30 months post-CAR-T infusion (latest follow-up March 2025)This case examines whether TP53-mutated, chemoresistant Burkitt lymphoma can nonetheless respond to CD19-directed CAR-T cell therapy, and what the underlying diagnostic, apoptotic, and metabolic evidence suggests about that outcome.
Read case→
CS-003not reported in the source

Durable Near-Complete Response to Pembrolizumab-Chemotherapy in BRAF Wild-Type Thyroid Cancer

A case of BRAF V600E wild-type, PD-L1-high anaplastic thyroid cancer that progressed on tyrosine kinase inhibitor therapy achieved a near-complete response lasting over 30 months on pembrolizumab combined with nab-paclitaxel and carboplatin.

Anaplastic Thyroid CancerSustained response followed for over 30 months from initiation of pembrolizumab-based triplet therapyExamines the evidence base for a sustained near-complete response to pembrolizumab combined with nab-paclitaxel and carboplatin in BRAF V600E wild-type, PD-L1-high anaplastic thyroid cancer following progression on multi-targeted tyrosine kinase inhibitor therapy.
Read case→
CS-002Metastatic HER2-positive breast cancer with active brain metastases (>20 lesions); no formal TNM stage reported

Long-Lasting Complete Intracranial Response to Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

A patient with HER2-positive breast cancer and more than 20 active brain metastases achieved a complete intracranial response to trastuzumab deruxtecan after progressing on WBRT and T-DM1, maintained for over 20 months.

HER2-positive breast cancerMore than 20 months of follow-up after initiation of third-line trastuzumab deruxtecanExamines a complete and durable intracranial response to trastuzumab deruxtecan (T-DXd) as third-line therapy in a patient with HER2-positive breast cancer and more than 20 active brain metastases who had progressed after whole-brain radiotherapy and trastuzumab emtansine (T-DM1).
Read case→
CS-001Advanced/metastatic, chemoresistant pancreatic adenocarcinoma; specific TNM stage not reported

Trametinib Plus Hydroxychloroquine in Two Patients with KRAS-Mutated Chemoresistant Pancreatic Cancer

A two-patient case series reports disease stabilization using trametinib plus hydroxychloroquine in chemoresistant, KRAS-mutant metastatic pancreatic adenocarcinoma, examined here against the underlying biological rationale and evidence quality.

KRAS-mutated advanced (metastatic) pancreatic ductal adenocarcinomaJanuary 2020 to time of publicationCase series evaluating trametinib (MEK inhibitor) combined with hydroxychloroquine (autophagy inhibitor) in two patients with KRAS-mutated, chemoresistant advanced pancreatic adenocarcinoma
Read case→

Canceria case studies are educational reference material. They should not be interpreted as individualized medical advice, diagnosis, or a recommendation for treatment.